drugset / Trial / NCT00303849

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

NCT00303849

NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.

Timeline

Start
2005-09-15
Primary completion
2021-03-12
Completion
2021-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Other
Subject Etoposide Small molecule Intravenous
Subject Melphalan Small molecule Other
Subject Etoposide Small molecule Intravenous
Background Mannitol Diagnostic / imaging agent Other
Background Sodium Thiosulfate Diagnostic / imaging agent Intravenous